Rochelle Strenger
Brown University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Rochelle Strenger.
Journal of Clinical Oncology | 2009
William M. Sikov; Don S. Dizon; Rochelle Strenger; Robert D. Legare; Kathy Puyana Theall; Theresa A. Graves; Jennifer Gass; Teresa Kennedy; Mary Anne Fenton
PURPOSE To evaluate the efficacy and safety of neoadjuvant carboplatin and weekly paclitaxel +/- weekly trastuzumab in resectable and locally advanced breast cancer. PATIENTS AND METHODS Women with stages IIA to IIIB disease received carboplatin dosed by six times the area under the curve every 4 weeks and paclitaxel 80 mg/m(2) weekly for 16 weeks, and weekly trastuzumab was added for human epidermal growth factor receptor 2 (HER2) -positive status. The primary end point was the pathologic complete response (pCR) rate, defined as the absence of invasive disease in the breast and axillary nodes. Postoperative therapies were at the discretion of the treating physicians. RESULTS Fifty-five patients were enrolled, and of these 43 had resectable disease. The median age was 54 years (range, 31 to 74 years). Treatment was well tolerated; there were no episodes of febrile neutropenia or grade 4 thrombocytopenia, and there were only two instances of grade 3 peripheral neuropathy. Overall, the pCR rate was 45%. The pCR rate was 43% (95% CI, 28% to 58%) in patients with resectable disease. Higher pCR rates occurred in patients with HER2-positive tumors (76% v 31% for HER2-negative tumors; P = .003), with estrogen receptor (ER) -negative tumors (75% v 27% for ER-positive tumors; P = .001), or with triple-negative tumors (67% v 12% ER-positive and HER2-negative tumors; P = .002). At a median of 28 months postoperation, recurrence-free survival (RFS) was 88.7%. If patients with ER-positive and HER2-negative tumors are excluded from analysis, patients who achieved a pCR were less likely to experience disease recurrence (RFS, 86%) than those who did not achieve a pCR (RFS, 75%). CONCLUSION Neoadjuvant carboplatin and weekly paclitaxel +/- trastuzumab achieve high pCR rates in patients with HER2-positive and triple-negative disease without exposure to an anthracycline. Preliminary RFS results are encouraging but are likely influenced by adjuvant therapy received. Additional study of this regimen in high-risk patients is warranted.
Obstetrics and Gynecology Clinics of North America | 2002
Robert D. Legare; Rochelle Strenger
The new millennium ushers in an exciting time in the treatment of early stage breast cancer. Although worldwide incidence statistics have not changed significantly in the past decade, mortality rates have declined. This change seems to be related to public health initiatives that increase early detection and awareness and to an increase in the efficacy of adjuvant treatments, including advances in chemotherapy and the emergence of biologic treatments. Physicians from many specialties participate in multidisciplinary tumor boards. Moreover, patients, families, and advocacy groups have taken on new responsibilities, offering encouragement and support for clinical and basic research.
Human Pathology | 1995
Lisa Goldstein; Rochelle Strenger; Thomas King; Stacy Comfort Le; Beverly Barton Rogers
A previously healthy 30-year-old African-American woman presented with a history of sickle cell trait and a nonspecific prodromal illness with severe bone pain. She experienced rapid clinical deterioration with seizures and cardiorespiratory arrest leading to death. Autopsy showed necrotic bone marrow with extensive bone marrow emboli. Parvovirus infection was documented by polymerase chain reaction (PCR) although diagnostic intranuclear inclusions or giant pronormoblasts were not present. The diagnosis of sickle cell-hemoglobin C disease (hemoglobin SC disease) was also established postmortem by DNA sequencing of PCR products. This case illustrates the use and versatility of PCR for analysis of formalin-fixed paraffin-embedded autopsy tissue.
American Journal of Surgery | 2007
Tarun Bhandari; Don S. Dizon; Charu Taneja; Jennifer Gass; Gabriela Masko; Rochelle Strenger
Journal of Clinical Oncology | 2005
William M. Sikov; Kathy Puyana Theall; C. W. Seidler; Rochelle Strenger; Mary Anne Fenton
American Journal of Hematology | 2000
F. López; Abeel A. Mangi; Rochelle Strenger; Fred J. Schiffman; Robert D. Meringolo
Journal of Clinical Oncology | 2017
Natalie Sinclair; Bachir J. Sakr; Maysa Abu-Khalaf; George Somlo; Robert C Black; Gina G. Chung; Tina Rizack; Rochelle Strenger; Mary Anne Fenton; Michael P. DiGiovanna; Maria Constantinou; Donald R. Lannin; Robert D. Legare; Anees B. Chagpar; Sundaresan Sambandam; Veerle Bossuyt; Kayla Rosati; Lyndsay Harris; William M. Sikov
Journal of Clinical Oncology | 2010
Tina Rizack; Maysa Abu-Khalaf; Robert D. Legare; Rochelle Strenger; Mary Anne Fenton; Bachir J. Sakr; Teresa Kennedy; Lyndsay Harris; William M. Sikov
Journal of Clinical Oncology | 2017
Natalie Sinclair; Maysa Abu-Khalaf; Tina Rizack; Kayla Rosati; Gina G. Chung; Robert D. Legare; Michael P. DiGiovanna; Mary Anne Fenton; Veerle Bossuyt; Rochelle Strenger; Bachir J. Sakr; Donald R. Lannin; Jennifer Gass; Lyndsay Harris; William M. Sikov
Journal of Clinical Oncology | 2011
Natalie Sinclair; Maysa Abu-Khalaf; Bachir J. Sakr; Tina Rizack; Donald R. Lannin; Jennifer Gass; Rochelle Strenger; Veerle Bossuyt; Mary Anne Fenton; Lyndsay Harris; William M. Sikov